CIM
PTCT icon

Cambria Investment Management’s PTC Therapeutics PTCT Stock Holding History

Cambria Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$724K Buy
10,625
+1,979
+23% +$140K 0.04% 287
2025
Q4 		$657K Sell
8,646
-2,988
-26% -$217K 0.04% 312
2025
Q3 		$714K Buy
11,634
+2,322
+25% +$121K 0.04% 276
2025
Q2 		$455K Buy
+9,312
New +$442K 0.03% 314

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Cambria Investment Management's PTCT Position: Q1 2026 in Review

Cambria Investment Management increased its PTC Therapeutics (PTCT) stake by 23% in Q1 2026, buying an estimated $140K and bringing the position to 10,625 shares worth $724K. The position accounts for 0.04% of the portfolio, ranked #287.

Cambria Investment Management first reported a position in PTCT in Q2 2025 and has held it in 4 quarters since. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Cambria Investment Management held 10,625 shares of PTC Therapeutics worth $724K as of Q1 2026.
  • Cambria Investment Management bought 1,979 PTC Therapeutics shares in Q1 2026, an estimated $140K.
  • PTC Therapeutics made up 0.04% of Cambria Investment Management's portfolio in Q1 2026, its #287 holding.
  • Cambria Investment Management first reported a position in PTC Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Cambria Investment Management's 13F filing for Q1 2026, filed 15 May 2026.